Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Julie Gralow, MD, shed light on the factors contributing to the growing shortage of oncologists in the US and what can be ...

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), particularly for patients with progressive or extensive disease. In locally ...

An expert discusses using sequence therapies based on disease progression, patient factors, and resistance mechanisms. After a first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor ...

Jennifer Marie Suga, MD, shares the lung cancer research she’s eager to explore as new data emerges. Jennifer Marie Suga, MD, ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care ...

The panelist discusses how for patients initially eligible for embolization, systemic therapy may be combined with ...